Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Journal of antimicrobial chemotherapy
- Publicado em
- 1 mai 2017
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB
Anushka Naidoo, Maxwell Chirehwa, Helen McIlleron, Kogieleum Naidoo, Sabiha Essack, Nonhlanhla Yende-Zuma, Eddy Kimba-Phongi, John Adamson, Katya Govender, Nesri Padayatchi et al.
Descritores MeSH
- HIV Infections
- Antibiotics, Antitubercular
- Rifampin
- Fluoroquinolones
- Benzoxazines
- Tuberculosis, Pulmonary
- Drug Therapy, Combination
- Female
- Humans
- Male
Veja também
Estudos relacionados
- Pharmacokinetics of rifampicin and isoniazid in patients with HIV-tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292-RIFAVIRENZ sub-study
- Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)
- Efficacy and safety of TDF+3TC + EFV‑centric antiretroviral regimens for HIV/HBV co-infection: a systematic review and network meta‑analysis
- Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine